中国医药
中國醫藥
중국의약
China Medicine
2015年
11期
1599-1601
,共3页
程玮涛%王宁%陈文劲%徐跃峤
程瑋濤%王寧%陳文勁%徐躍嶠
정위도%왕저%진문경%서약교
重型颅脑创伤%氨溴索%肺部感染
重型顱腦創傷%氨溴索%肺部感染
중형로뇌창상%안추색%폐부감염
Traumatic brain injury%Mucosolvan%Pulmonary infection
目的 探讨不同剂量氨溴索对重型颅脑创伤并发肺部感染患者的治疗效果.方法 选择于2012年1月至2014年6月在首都医科大学宣武医院住院的重型颅脑创伤并发肺部感染患者60例,完全随机分为A、B、C3组,各20例.所有患者采用常规降低颅内压、抗癫痫、抗感染等对症支持治疗,叩背、排痰等常规护理,其中A组不使用氨溴索治疗,B组采用600 mg/d氨溴索持续静脉滴注,C组采用30 mg氨溴索,3次/d,静脉滴注,B、C组均采用氨溴索雾化吸入.在治疗第7、14天观察、比较3组患者总有效率、感染控制率和感染控制时间.结果 治疗第14天,B组总有效率明显高于A组和C组[80.0％ (16/20)比25.0％ (5/20)、75.0％ (15/20)],差异有统计学意义(P＜0.05);B组治疗第14天感染控制率明显高于治疗第7天和A组、C组同时间[80.0％(16/20)比70.0％ (14/20)、25.0％(5/20)、75.0％ (15/20)],差异有统计学意义(P＜0.05).治疗第14天,与A组、C组比较,B组感染控制时间明显缩短[(9.8±1.1)d比(11.2±1.4)、(10.2±1.4)d],差异有统计学意义(P＜0.05).结论 重型颅脑创伤并发肺部感染患者采用大剂量氨溴索治疗,能提高治疗的总有效率,在较短时间内控制感染.
目的 探討不同劑量氨溴索對重型顱腦創傷併髮肺部感染患者的治療效果.方法 選擇于2012年1月至2014年6月在首都醫科大學宣武醫院住院的重型顱腦創傷併髮肺部感染患者60例,完全隨機分為A、B、C3組,各20例.所有患者採用常規降低顱內壓、抗癲癇、抗感染等對癥支持治療,叩揹、排痰等常規護理,其中A組不使用氨溴索治療,B組採用600 mg/d氨溴索持續靜脈滴註,C組採用30 mg氨溴索,3次/d,靜脈滴註,B、C組均採用氨溴索霧化吸入.在治療第7、14天觀察、比較3組患者總有效率、感染控製率和感染控製時間.結果 治療第14天,B組總有效率明顯高于A組和C組[80.0％ (16/20)比25.0％ (5/20)、75.0％ (15/20)],差異有統計學意義(P＜0.05);B組治療第14天感染控製率明顯高于治療第7天和A組、C組同時間[80.0％(16/20)比70.0％ (14/20)、25.0％(5/20)、75.0％ (15/20)],差異有統計學意義(P＜0.05).治療第14天,與A組、C組比較,B組感染控製時間明顯縮短[(9.8±1.1)d比(11.2±1.4)、(10.2±1.4)d],差異有統計學意義(P＜0.05).結論 重型顱腦創傷併髮肺部感染患者採用大劑量氨溴索治療,能提高治療的總有效率,在較短時間內控製感染.
목적 탐토불동제량안추색대중형로뇌창상병발폐부감염환자적치료효과.방법 선택우2012년1월지2014년6월재수도의과대학선무의원주원적중형로뇌창상병발폐부감염환자60례,완전수궤분위A、B、C3조,각20례.소유환자채용상규강저로내압、항전간、항감염등대증지지치료,고배、배담등상규호리,기중A조불사용안추색치료,B조채용600 mg/d안추색지속정맥적주,C조채용30 mg안추색,3차/d,정맥적주,B、C조균채용안추색무화흡입.재치료제7、14천관찰、비교3조환자총유효솔、감염공제솔화감염공제시간.결과 치료제14천,B조총유효솔명현고우A조화C조[80.0％ (16/20)비25.0％ (5/20)、75.0％ (15/20)],차이유통계학의의(P＜0.05);B조치료제14천감염공제솔명현고우치료제7천화A조、C조동시간[80.0％(16/20)비70.0％ (14/20)、25.0％(5/20)、75.0％ (15/20)],차이유통계학의의(P＜0.05).치료제14천,여A조、C조비교,B조감염공제시간명현축단[(9.8±1.1)d비(11.2±1.4)、(10.2±1.4)d],차이유통계학의의(P＜0.05).결론 중형로뇌창상병발폐부감염환자채용대제량안추색치료,능제고치료적총유효솔,재교단시간내공제감염.
Objective To investigate the effect of different doses of mucosolvan on severe traumatic brain injury complicated with pulmonary infection.Methods Sixty patients with severe traumatic brain injury complicated with pulmonary infection from January 2012 to June 2014 were randomly divided into group A, B and C (20 cases in each group).All patients were given symptomatic and supportive treatment including the intracranial pressure reduction, anti-epilepsy, anti-infection and routine care (knocking back, expectoration);group B was additionally administrated with continuous infusion of mucosolvan 600 mg/d;group C was additionally administrated with infusion of mucosolvan 30 mg/time, 2 times/d;group B and C were both given mucosolvan inhalation.After 7 and 14 days of treatment, the total effective rate, infection control rate and infection control time were compared among the three groups.Results After 14 days of treatment, the total effective rate and infection control rate in group B were significantly higher than those in group A and group C [80.0％ (16/20) vs 25.0％ (5/20), 75.0％ (15/20);80.0％ (16/20) vs 25.0％ (5/20), 75.0％ (15/20)] (P＜0.05);in group B, the infection control rate 14 days after treatment was also higher than that 7 days after treatment [80.0％ (16/20) vs 70.0％ (14/20)] (P ＜ 0.05).After 14 days of treatment, the infection control time in group B was significantly longer than that in group A and group C [(9.8 ±1.1) d vs (11.2±1.4), (10.2±1.4) d] (P＜0.05).Conclusion Large doses of mucosolvan can not only improve the overall efficiency, but also control the infection in a short time in patients with severe brain injury complicated with lung infections.
